PROVECTUS BIOPHARMACEUTICALS, INC. cotiza a 0.05 USD y tiene una capitalización bursátil de $23M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs …
| Periodo | 2013-03 | 2012-11 | 2012-08 | 2012-05 |
|---|---|---|---|---|
| Real | $-0.02 | $-0.02 | $-0.03 | $-0.04 |
| Estimado | $-0.03 | $-0.03 | $-0.03 | $-0.04 |
| Sorpresa | +33.3% | +33.3% | +0.0% | +0.0% |
| Métrica | PVCT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1575.3% | -38.6% | -1536.7% |
| Net Margin | -1615.8% | -33.6% | -1582.3% |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -778.6% | -32.0% | -746.6% |
| Current Ratio | 0.08 | 2.84 | -2.76 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |